Idiopathic pulmonary fibrosis (IPF) is a rare, progressive lung disease that greatly impacts patients' quailty of life and diminishes life expectancy. New therapies are available that slow function decline. These therapies are used in combination with oxygen supplementation, pulmonary rehabilitation, symptomatic treatment, and supportive care. This program will discuss the prevalence, signs and symptoms, and diagnostic criteria for IPF as well as compare and contrast available therapies and formulate strategies for comprehensive management of symptoms.
This course is approved for 1.0 CRCE.
**Please note that all programs require the participant to view the entire program prior to taking the final quiz and obtaining a course certificate.**
This activity is sponsored by the Academy for Continued Healthcare Learning and supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc.
- Identify patients with IPF who may benefits from intensification of therapy
- Outline the prevalence, signs and symptoms, and diagnostic criteria for IPF
- Effectively counsel IPF patients on available therapies and supportive care
- Formulate strategies for comprehensive management of symptoms
- Compare and contrast available therapies for IPF